Rituximab for nivolumab plus ipilimumabinduced encephalitis in a small-cell lung cancer patient

Annals of Oncology

Volumn 28, Issue 9, 2017, Pages 2318-2319

  Ito, M ^a   Fujiwara, S ^a   Fujimoto, D ^a   Mori, R ^a   Yoshimura, H ^a   Hata, A ^b   Kohara, N ^a   Tomii, K ^a  

^a KOBE CITY MEDICAL CENTER GENERAL HOSPITAL   (Japan)

^b INSTITUTE OF BIOMEDICAL RESEARCH AND INNOVATION   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

CARBOPLATIN; ETOPOSIDE; IMMUNOGLOBULIN; IPILIMUMAB; METHYLPREDNISOLONE; NIVOLUMAB; RITUXIMAB; ANTINEOPLASTIC AGENT; MONOCLONAL ANTIBODY;

AGED; BRAIN METASTASIS; BRAIN SURGERY; CANCER GROWTH; CANCER PATIENT; CASE REPORT; CEREBROSPINAL FLUID ANALYSIS; CLINICAL ARTICLE; COMPUTER ASSISTED TOMOGRAPHY; CONVULSION; DRUG RESPONSE; DRUG WITHDRAWAL; ELECTROENCEPHALOGRAPHY; ENCEPHALITIS; FOLLOW UP; HUMAN; LETTER; LUMBAR PUNCTURE; MAINTENANCE THERAPY; MALE; MULTIPLE CYCLE TREATMENT; NUCLEAR MAGNETIC RESONANCE IMAGING; PLEOCYTOSIS; PRIORITY JOURNAL; PROTEIN CEREBROSPINAL FLUID LEVEL; SMALL CELL LUNG CANCER; WHOLE BRAIN RADIOTHERAPY; BRAIN TUMOR; CEREBROSPINAL FLUID; CHEMICALLY INDUCED; LUNG TUMOR; PATHOLOGY; SECONDARY;

AGED; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BRAIN NEOPLASMS; ENCEPHALITIS; HUMANS; IPILIMUMAB; LUNG NEOPLASMS; MALE; RITUXIMAB; SMALL CELL LUNG CARCINOMA;

EID: 85029825845     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdx252     Document Type: Letter

References (5)

1. Wolchok JD, Kluger H, Callahan MK et al. Nivolumab plus ipilimumab in advanced melanoma. N Engl J Med 2013; 369: 122-133
2. Postow MA, Chesney J, Pavlick AC et al. Nivolumab and ipilimumab versus ipilimumab in untreated melanoma. N Engl J Med 2015; 372: 2006-2017
3. Larkin J, Chiarion-Sileni V, Gonzalez R et al. Combined nivolumab and ipilimumab or monotherapy in untreated melanoma. N Engl J Med 2015; 373: 23-34
4. Antonia SJ, López-Martin JA, Bendell J et al. Nivolumab alone and nivolumab plus ipilimumab in recurrent small-cell lung cancer (CheckMate 032): a multicentre, open-label, phase 1/2 trial. Lancet Oncol 2016; 17: 883-895
5. Williams TJ, Benavides DR, Patrice KA et al. Association of autoimmune encephalitis with combined immune checkpoint inhibitor treatment for metastatic cancer. JAMA Neurol 2016; 73: 928-933